BioXcel Therapeutics, Inc. Stock-Based Compensation
BioXcel Therapeutics, Inc. (BTAI) reported Stock-Based Compensation of $793.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- BioXcel Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $358.00K, a 76.99% decline year-over-year.
- BioXcel Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $435.00K, a 141.67% increase year-over-year.
- BioXcel Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $450.00K.
- BioXcel Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $581.00K, a 68.85% decline year-over-year.
- BioXcel Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $2.77M, a 55.05% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $6.16M, a 66.93% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $18.61M, a 7.37% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $17.34M, a 10.89% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $358.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $793.00K 10-Q · filed 2026-08-13 | $1.24M derived: sum of 3 quarters · filed 2026-08-13 | $1.82M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $435.00K 10-Q · filed 2026-05-15 | $885.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.47M derived: sum of 3 quarters · filed 2026-05-15 | $3.02M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.03M derived: sum of 2 quarters · filed 2026-03-27 | $2.59M derived: sum of 3 quarters · filed 2026-08-13 | $2.77M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $581.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.14M derived: sum of 2 quarters · filed 2026-08-13 | $2.32M 10-Q · filed 2025-11-12 | $2.12M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.74M 10-Q · filed 2026-08-13 | $1.54M derived: sum of 3 quarters · filed 2026-08-13 | $3.40M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $180.00K 10-Q · filed 2026-05-15 | -$19.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.85M derived: sum of 3 quarters · filed 2026-05-15 | $2.90M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.67M derived: sum of 2 quarters · filed 2026-03-27 | $2.72M derived: sum of 3 quarters · filed 2026-03-27 | $6.16M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.92M derived: sum of 2 quarters · filed 2025-11-12 | $6.36M 10-Q · filed 2025-11-12 | $9.95M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $4.49M 10-Q · filed 2025-08-12 | $8.09M derived: sum of 3 quarters · filed 2025-08-12 | $12.10M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $3.43M 10-Q · filed 2025-05-12 | $7.03M derived: sum of 2 quarters · filed 2025-05-12 | $11.05M derived: sum of 3 quarters · filed 2025-05-12 | $17.17M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $7.61M derived: sum of 2 quarters · filed 2025-03-28 | $13.74M derived: sum of 3 quarters · filed 2025-03-28 | $18.61M 10-K · filed 2025-03-28 | |
| 2023-09-30 | $4.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $10.14M derived: sum of 2 quarters · filed 2024-11-14 | $15.02M 10-Q · filed 2024-11-14 | $19.56M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $6.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $11.00M 10-Q · filed 2024-08-06 | $15.55M derived: sum of 3 quarters · filed 2024-08-06 | $20.03M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | $4.88M 10-Q · filed 2024-05-09 | $9.42M derived: sum of 2 quarters · filed 2024-05-09 | $13.91M derived: sum of 3 quarters · filed 2024-05-09 | $18.39M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $9.03M derived: sum of 2 quarters · filed 2024-03-22 | $13.51M derived: sum of 3 quarters · filed 2024-03-22 | $17.34M 10-K · filed 2024-03-22 | |
| 2022-09-30 | $4.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $8.96M derived: sum of 2 quarters · filed 2023-11-14 | $12.79M 10-Q · filed 2023-11-14 | $15.03M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $4.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $8.31M 10-Q · filed 2023-08-14 | $10.54M derived: sum of 3 quarters · filed 2023-08-14 | $15.43M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $3.83M 10-Q · filed 2023-05-09 | $6.06M derived: sum of 2 quarters · filed 2023-05-09 | $10.95M derived: sum of 3 quarters · filed 2023-05-09 | $17.71M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $7.12M derived: sum of 2 quarters · filed 2023-03-16 | $13.89M derived: sum of 3 quarters · filed 2023-03-16 | $19.45M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $11.65M derived: sum of 2 quarters · filed 2022-11-14 | $17.22M 10-Q · filed 2022-11-14 | $23.83M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $6.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $12.33M 10-Q · filed 2022-08-11 | $18.95M derived: sum of 3 quarters · filed 2022-08-11 | $24.21M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $5.57M 10-Q · filed 2022-05-09 | $12.18M derived: sum of 2 quarters · filed 2022-05-09 | $17.44M derived: sum of 3 quarters · filed 2022-05-09 | $19.40M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $6.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $11.88M derived: sum of 2 quarters · filed 2022-03-11 | $13.84M derived: sum of 3 quarters · filed 2022-03-11 | $14.61M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $5.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $7.22M derived: sum of 2 quarters · filed 2021-11-10 | $8.00M 10-Q · filed 2021-11-10 | $8.65M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $2.73M 10-Q · filed 2021-08-10 | $3.39M derived: sum of 3 quarters · filed 2021-08-10 | $4.16M derived: sum of 4 quarters · filed 2021-08-10 | |
| 2020-03-31 | $776.00K 10-Q · filed 2021-05-10 | $1.43M derived: sum of 2 quarters · filed 2021-05-10 | $2.21M derived: sum of 3 quarters · filed 2021-05-10 | $3.24M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $654.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $1.43M derived: sum of 2 quarters · filed 2021-03-12 | $2.46M derived: sum of 3 quarters · filed 2021-03-12 | $3.14M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $776.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.81M derived: sum of 2 quarters · filed 2020-11-12 | $2.49M 10-Q · filed 2020-11-12 | $2.62M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $1.71M 10-Q · filed 2020-08-14 | $1.84M derived: sum of 3 quarters · filed 2020-08-14 | $2.73M derived: sum of 4 quarters · filed 2020-08-14 | |
| 2019-03-31 | $682.00K 10-Q · filed 2020-05-12 | $815.00K derived: sum of 2 quarters · filed 2020-05-12 | $1.71M derived: sum of 3 quarters · filed 2020-05-12 | $2.44M derived: sum of 4 quarters · filed 2020-05-12 | |
| 2018-12-31 | $133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $1.02M derived: sum of 2 quarters · filed 2020-03-09 | $1.76M derived: sum of 3 quarters · filed 2020-03-09 | $3.08M 10-K · filed 2020-03-09 | |
| 2018-09-30 | $890.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.63M derived: sum of 2 quarters · filed 2019-11-14 | $2.95M 10-Q · filed 2019-11-14 | $4.04M derived: sum of 4 quarters · filed 2019-11-14 | |
| 2018-06-30 | $740.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $2.06M 10-Q · filed 2019-08-06 | $2.06M 10-Q · filed 2018-08-08 | $3.15M derived: sum of 3 quarters · filed 2019-08-06 | $3.46M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $1.32M 10-Q · filed 2019-05-07 | $2.41M derived: sum of 2 quarters · filed 2019-05-07 | $2.73M derived: sum of 3 quarters · filed 2019-05-07 | $2.82M derived: sum of 4 quarters · filed 2019-05-07 | |
| 2017-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $1.41M derived: sum of 2 quarters · filed 2019-03-12 | $1.50M derived: sum of 3 quarters · filed 2019-03-12 | $1.61M 10-K · filed 2019-03-12 | |
| 2017-09-30 | $316.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $409.00K derived: sum of 2 quarters · filed 2018-11-09 | $516.00K 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $200.00K 10-Q · filed 2018-08-08 | |||
| 2017-03-31 | $107.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |